ANZUP Conference Presentations 2021
ASCO GU 2021 - Virtual Meeting - 11 - 13 February 2021
- Abstract TPS266: DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP 1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
First Author: Tamim Niazi, MD
- Abstract TPS367: Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP 1601).
First Author: Craig Gedye, PhD, FRACP
-
Abstract TPS390: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
First Author: Shalini Subramaniam, MBBS
-
Abstract TPS177: ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett, FRACP, MBChB, MD
-
Abstract 325: UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.
First Author: Craig Gedye, FRACP, MBChB, PhD
ANZUP Conference Presentations 2020
ASCO 2020 - Virtual Meeting - 29 May - 2 June 2020
- Hofman, M et al., TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel - initial results (ANZUP protocol 1603). Oral presentation.
ASCO GU 13-15 February 2020 - Trials in progress posters:
- Abstract TPS385: DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.
First Author: Tamim Niazi, MD
- Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
First Author: Andrew Weickhardt, FRACP, MBBS
-
Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
First Author: Shalini Subramaniam, MBBS
-
Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).
First Author: Elizabeth Liow, MBBS, FRACP
-
Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.
First Author: Craig Gedye, PhD, FRACP
ANZUP Journal Articles 2021
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y Zhang, Margaret M McJannett, Martin R Stockler, John A Violet, Scott G Williams, Andrew J Martin, Ian D Davis for the Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 11 February 2021.
ANZUP Journal Articles 2020
Michael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Ramdave Shakher, Lih-Ming Wong, Kim Taubman, Sze Ting Lee, Edward Hsiao, Paul Roach, Michelle Nottage, Ian Kirkwood, Dickon Hayne, Emma Link, Petra Marusic, Anetta Matera, Alan Herschtal, Amir Iravani, Rodney J Hicks, Scott Williams, Declan G Murphy, for the proPSMA Study Group Collaborators*. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet, 22 March 2020.
ANZUP Journal Articles 2019
Ian D. Davis, M.B., B.S., Ph.D., Andrew J. Martin, Ph.D., Martin R. Stockler, M.B., B.S., Stephen Begbie, M.B., B.S., Kim N. Chi, M.D., Simon Chowdhury, M.B., B.S., Ph.D., Xanthi Coskinas, M.Med.Sc., Mark Frydenberg, M.B., B.S., Wendy E. Hague, M.B., B.S., Ph.D., Lisa G. Horvath, M.B., B.S., Ph.D., Anthony M. Joshua, M.B., B.S., Ph.D., Nicola J. Lawrence, M.B., Ch.B., Gavin Marx, M.B., B.S., John McCaffrey, M.B., B.Ch., Ray McDermott, M.D., Ph.D., Margaret McJannett, R.N., Scott A. North, M.D., Francis Parnis, M.B., B.S., Wendy Parulekar, M.D., David W. Pook, M.B., B.S., M.D., M. Neil Reaume, M.D., Shahneen K. Sandhu, M.B., B.S., Alvin Tan, M.B., Ch.B., T. Hsiang Tan, M.B., B.S., Alastair Thomson, B.M., Emily Tu, Ph.D., Francisco Vera-Badillo, M.D., Scott G. Williams, M.B., B.S., M.D., Sonia Yip, Ph.D., Alison Y. Zhang, M.B., B.S., Robert R. Zielinski, M.B., B.S., and Christopher J. Sweeney, M.B., B.S. for the ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group*. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. NEJM, 2 June 2019.
Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW; ANZUP Cancer Trials Group, Davis ID. Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJUI Int. 2019;123(1):22-34. doi: 10.1111/bju.14489. BJUI, January 2019.
Michael S. Hofman, Louise Emmett, John Violet, Alison Zhang, Nicky J. Lawrence, Martin Stockler, Roslyn J. Francis, Amir Iravani, Scott Williams, Arun Azad, Andrew Martin, Margaret McJannett, ANZUP TheraP team, Ian D. Davis. TheraP: a randomised phase 2 trial of 177Lu-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer: (ANZUP 1603). BJUI, submitted March 2019.
ANZUP Conference Presentations 2019
Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial. ESMO 2019 Congress Poster Discussion presentation by Professor Martin Stockler on 29 September 2019.
Primary Efficacy Analysis Results From The SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double blind phase III trial led by the MRC CTU at UCL. ESMO 2019 Congress presentation by Professor Tim Eisen on behalf of the SORCE Trial Management Group on 28 September 2019.
Overall survival (OS) Results of a Phase III Randomized Trial of Standard of Care Therapy with or without enzalutamide for a Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP –led International Co-operative Group Trial. MOGA ASM presentation by Professor Ian D. Davies on Friday 16 August 2019.
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. ASCO Plenary presentation by Professor Christopher J. Sweeney, MMBS on 2 June 2019.
An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP 1302). ASCO GU, 14-16 February 2019.
TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer. ASCO GU, 14 - 16 February 2019.
Dr Simeon Ngweso – Villas Marshall Prize Winner, Penile cancer in Western Australia: “Discrepancies in registry Coding for Penile cancer” and “The significance of demographic location in survival outcomes". USANZ ASM 2019.
ANZUP Journal Articles 2018
What survival benefits are needed to make Adjuvant Sorafenib worthwhile after resection of intermediate – or high-risk renal cell carcinoma? Clinical investigators’ preferences in the SORCE Trial. Kidney Cancer 2 (2018) 123–131. doi: 10.3233/KCA-180038. 16 July, 2018
P3BEP (ANZUP 1302): An international randomised phase III trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Alison Yan Zhang, Guy C. Toner, Nicola Jane Lawrence, Martin R. Stockler, Andrew James Martin, Kate Ford, Amanda Gwendolyn Stevanovic, David Wyld, Euan Thomas Walpole, Simon Troon, Fritha J. Hanning, Girish Mallesara, Andrew James Weickhardt, Alison Jane Birtle, Ian D. Davis, Peter S. Grimison. Journal of Clinical Oncology.
Williams S. GDPR – not just an EU regulation? Lancet Oncol. 2018;19(10):e508. doi: 10.1016/S1470- 2045(18)30696-X. Lancet Oncology, October 2018.
Alison Yan Zhang, Guy C. Toner, Nicola Jane Lawrence, Martin R. Stockler, Andrew James Martin, Kate Ford, Amanda Gwendolyn Stevanovic, David Wyld, Euan Thomas Walpole, Simon Troon, Fritha J. Hanning, Girish Mallesara, Andrew James Weickhardt, Alison Jane Birtle, Ian D. Davis, Peter S. Grimison. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal of Clinical Oncology. 26 February 2019.
Michael Hofman, Louise Emmett, John A Violet, Nicola Jane Lawrence, Scott Williams, Martin R. Stockler, Roslyn J Francis, Amir Iravani, Alison Yan Zhang, Andrew James Martin, Arun Azad, Sonia Yip, Ailsa Langford, Margaret Mary McJannett, Ian D. Davis. A randomized phase II trial of [177Lu]- PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer. Journal of Clinical Oncology.
ANZUP Conference Presentations 2018
Randomised phase 3 trial of enzlautamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303). American Society of Clinical Oncology – Genitourinary Cancers, San Francisco, February 2018.
Nayar N, Lawrence N, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn DI, McDermott R, Walker R, Winstanley M, Hanning FJ, Weickhardt A, Stevanovic A, Davis ID, Toner GC, Grimison PS. An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor risk metastatic germ cell tumours: P3BEP (ANZUP 1302) American Society of Clinical Oncology – Genitourinary Symposium; 8–10 February 2018.
Srikala S Sridhar et al. Abstract #219679 CCTG BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen. 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, McCormick Place, Chicago, IL, USA. 1-5 June 2018.
M. Stockler, et al. The ANZUP Phase 3 Accelerated BEP trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours. ASCO, Chicago, USA. 1-5 June, 2018.
Crossing the paediatric and adult hospital divide: An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. 3rd AYA congress, 4-6 December, 2018
ANZUP Journal Articles 2017
Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP. Mindfulness-based cognitive therapy in advanced prostate cancer: A randomized controlled trial. Journal of Clinical Oncology 2017; 35(3): 291-297.
Hayne D, Stockler M, McCombie SP, Lawrence N, Martin A, Sengupta S. The BCG+ Mitomycin trial for high risk non-muscle-invasive bladder cancer: Progress report and lessons learned. Brit J Urol Int 2017.
Heiniger, L. E., Smith, A. B., Olver, I., Grimison, P., Klein, B., Wootten, A., Butow, P. N. (2017). e-TC: Development and pilot testing of a web-based
intervention to reduce anxiety and depression in survivors of testicular cancer. Eur J Cancer Care (Engl), 26(6). doi:10.1111/ecc.12698.
ANZUP Conference Presentations 2017
Lawrence N J, Martin A, Davis I D, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Ritchie A W S, Meade A, Eisen T, Blinman P, Stockler M R. Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial. Poster presentation at European Society for Medical Oncology (ESMO) 2017: 8–12 September 2017, Madrid, Spain.
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for clinically localised high risk or node-positive prostate cancer: the ENZARAD Trial (ANZUP 1303). American Society of Clinical Oncology, Chicago, June 2017.
Grimison P, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, Walker R, Winstanley M, Hanning F,
Weickhardt A, Stevanovic A, Davis I, Toner G. P3 BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). American Society of Clinical Oncology; 2–6 June 2017; Chicago, Illinois.
Nayar N, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, Walker R, Winstanley M, Hanning F,
Weickhardt A, Stevanovic A, Davis I, Toner G, Grimison P. P3 BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia; 13–15 November 2017; Sydney.
ANZUP Journal Articles 2016
Smith AB, Butow P, Olver I, Luckett T, Grimison P, Toner GC, Stockler MR, Hovey E, Stubbs J, Turner S, Hruby G, Gurney H, Alam M, Cox K, King MT. The prevalence, severity and correlation of psychological distress and impaired healthrelated quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship: Research and Practice 2016; 10(2): 223-233.
Ussher JM, Perz J, Kellett A, Chambers S, Latini D, Davis ID, Rose D, Dowsett GW, Williams S. Health-related quality of life, psychological distress and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. Journal of Sexual Medicine 2016; 13(3): 425-434.
Rose, D., Ussher, J., & Perz, J. (2016). Let’s talk about gay sex: Gay and bisexual men’s sexual communication with healthcare professionals after prostate cancer. European Journal of Cancer Care (Engl), [published online ahead of print]. doi: 10.1111/ ecc.12469.
Ussher J. M., Perz, J., Rose, D., Dowsett, G. W., Chambers, S., Williams, S., Davis I, Latini, D. (2016). Threat of sexual disqualification: The consequences of erectile dysfunction and other sexual changes for gay and bisexual men with prostate cancer. Archives of Sexual Behaviour DOI 10.1007/s10508-016- 0728-0 [available open access].
Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, Stockler MR, Lepore SJ, Frydenberg M, Gardiner RA, Davis ID, Smith DP. The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Quality of Life Research 2016; 25(12): 3027–3035.
Lawrence N, Martin A, Toner G, Stockler M, Buizen L, Thomson D, Gebski V, Friedlander M, Yeung A, Wong N, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong S, Lewis C, Vasey P, Grimison P. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group [letter]. Annals of Oncology 2016; 27(12): 2302–2303.
McCombie S, Chang D, Sengupta S, Stockler M, Davis I, Hayne D. Moving toward an evidence and consensus based multicentre enhanced recovery pathway for radical cystectomy: results of an ANZUP survey. BJU International 2016; 117: 98–99.
Roncolato FT, Chatfield M, Houghton B, Toner G, Stockler M, Thomson D, Friedlander M, Gurney H, Rosenthal M, Grimison P. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal 2016; 46(8): 893–898
ANZUP Conference Presentations 2016
Toner GC, Whitford HS, Kalinowski P, Grimison PS, Stockler MR, Martin AJ, Davis ID, Olver IN, ANZUP Cancer Trials Group. The impact of chemotherapy on cognition: a longitudinal study in testicular cancer. Genitourinary Cancers Symposium; 7–9 Jan 2016; San Francisco.
Lawrence, N. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial. Oral presentation in session: Best of the Best Research in 2016, Medical Oncology Group of Australia Annual Scientific Meeting 2016, August 3-5, Gold Coast, Australia.
Lawrence, N. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial. ANZUP Annual Scientific Meeting 2016, July 10-12, Brisbane, Australia.
All interviews and presentations from the ANZUP ASM are available to ANZUP Members only. Membership is free for professional disciplines and groups involved in researching and treating cancers of the genitourinary system.
ANZUP Journal Articles 2015
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith
DP. An examination of prostate cancer trends in Australia,
England, Canada and USA: is the Australian death rate too
high? World Journal of Urology 2015; 33(11): 1677–1687.
Hayne D, Stockler M, McCombie SP, Chalasani V, Long A,
Martin A, Sengupta S, Davis ID. BCG+MMC trial: adding
mitomycin C to BCG as adjuvant intravesical therapy for highrisk,
non-muscle-invasive bladder cancer: a randomised phase
III trial (ANZUP 1301). BMC Cancer 2015; 15(1): 432.
Sengupta S, Grimison P, Hayne D, Williams S, Chambers S,
de Souza P, Stockler M, McJannett M, Toner G, Davis ID.
ANZUP—a new co-operative cancer trials group in genitourinary
oncology. BJU International 2015; 115(6): 856-858.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi
K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza
H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis
ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME,
Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis
CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker
C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small
EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF & Tombal
B: Management of patients with advanced prostate cancer:
recommendations of the St Gallen Advanced Prostate Cancer
Consensus Conference (APCCC) 2015, Annals of Oncology
Advance Access, 28 June, 2015.
ANZUP Conference Presentations 2015
Blinman P, Davis I, Martin A, Troon S, Sengupta S, Hovey E,
Coskinas X, Kaplan R, Ritchie A, Meade A, Eisen T, Stockler
M. Patients’ preferences for adjuvant sorafenib after resection
of intermediate or high risk renal cell carcinoma in the sorce
trial: What makes it worthwhile? Medical Oncology Group of
Australia Annual Scientific Meeting; 5–7 Aug 2015; Hobart.
Davis ID, Stockler MR, Martin AJ, Marchesin V, Deignan O,
McDermott R, Parulekar WR, North SA, Graham B, Long AP,
Roncolato FT, Yip S, Hague W, Dazo C, Coskinas X, Sweeney C.
Randomised phase 3 trial of enzalutamide in first line androgen
deprivation therapy for metastatic prostate cancer: the ANZUP
ENZAMET trial (ANZUP 1304). American Society of Clinical
Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.
Lawrence N, Toner G, Martin A, Stockler M, Yeung A, Wong N,
Thomson DB, Gebski V, Yip S, King M, Friedlander M, Quinn D,
Tan TH, Chan H, Mazhar D, Hanning F, Weickhardt A, Jeffery M,
Stevanovic A, Hovey E, Wyld D, Davis ID, Grimison P, and on
behalf of ANZUP. P3 BEP (ANZUP 1302): a randomised phase
3 trial of accelerated versus standard BEP chemotherapy for
patients with intermediate and poor-risk metastatic germ cell
tumours. Clinical Oncological Society of Australia 42nd Annual
Scientific Meeting; 17–19 Nov 2015; Hobart.
Williams SG, Davis ID, Sweeney C, Stockler MR, Martin AJ,
Marchesin V, Deignan O, McDermott R, Long AP, Roncolato
FT, Yip S, Hague W, Tu E, Coskinas X, Nguyen PL. Randomised
phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised prostate
cancer: the ANZUP ENZARAD trial (ANZUP 1303). American
Society of Clinical Oncology Annual Meeting; 29 May−2 Jun
2015; Chicago.
Ussher, JM: Sexual wellbeing and quality of life after prostate
cancer: A comparison of gay/ bisexual men and heterosexual
men, ANZUP Annual Scientific Meeting, 12-14 July 2015; Sydney.
Ussher, JM; Gay and bisexual men’s experiences of sexuality,
identity and relationships after prostate cancer: A qualitative
analysis, ANZUP Annual Scientific Meeting, 12-14 July 2015;
Sydney.
Yip S, Hague W, Price T, Mitchell P, Davis ID; Brand A;
Rosenthal M; Simes RJ, Stockler MR: Pursuing Biospecimens
Translational Research in Investigator-Initiated Clinical Trials in
Oncology, ACTA International Clinical Trials Symposium, 7-10
October 2015; Sydney
Nguyen P, Williams S, Davis I, Stockler M, Niazi T: Randomised
phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised, prostate
cancer, ANZUP Annual Scientific Meeting, July 2015; Sydney.
Grummet J, Davis I, Martin A, Buchan N, Chalasani V,
Frydenberg M, Hayne D, Lalak A, Patel M, Williams A, Woo H,
Lawrence N, Chan H, Bishop C, Wong N, Coskinas X, Stockler
M: Randomised phase 3 double-blind placebo-controlled
trial of methoxyflurane with periprostatic local anaesthesia
to reduce the discomfort of transrectal ultrasound-guided
prostate biopsy (Pain-Free TRUS B): ANZUP 1501, Clinical
Oncology Society of Australia Annual Scientific Meeting; 17-19
Nov 2015; Hobart.
Davis ID, Stockler MR, Martin A, Marchesin V, Deignan O,
McDermott R, Parulekar WR, North SA, Graham B, Chowdhury
S, Long AP, Roncolato FT, Yip S, Hague W, Dazo C, Coskinas
X, Sweeney C: Randomised phase 3 trial of enzalutamide in
first line androgen deprivation therapy for metastatic prostate
cancer: the ANZUP ENZAMET Trial (ANZUP 1304). American
Society of Clinical Oncology Annual Meeting; 29 May−2 Jun
2015; Chicago.
Williams SG, Davis IDD, Sweeney C, Stockler MR, Martin
A, Hague W, Coskinas X, Yip S, Tu E, Chan H, Lawrence N,
McDermott R, Hughes S, Marchesin V, Deignan O, Nguyen
PL: Randomised phase 3 trial of enzalutamide in androgen
deprivation therapy (ADT) with radiation therapy for clinically
localised high risk or node-positive, clinically localized, prostate
cancer: ENZARAD (ANZUP 1303). American Society of Clinical
Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.